Navigation Links
Epygenix Therapeutics Receives US FDA Orphan Drug Designation for EPX-300 for the Treatment of Patients With Dravet Syndrome
Date:8/23/2017

PARAMUS, N.J., Aug. 23, 2017 /PRNewswire/ -- Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for rare and catastrophic forms of genetic epilepsy, announced today that the U.S. Food and Drug Administration has granted Orphan Drug Designation for EPX-300 for the treatment of patients with Dravet Syndrome. Dravet Syndrome qualifies as a rare pediatric disease under Section 529 of the Food, Drug, and Cosmetic Act.

Dravet Syndrome, a lifelong form of epilepsy, begins in the first year of life with frequent or prolonged seizures. Intellectual disability, behavioral abnormalities, gait and motor dysfunction, and increased mortality are commonly observed as the disease progresses. Patients with Dravet Syndrome also suffer with life-threatening seizures that cannot be adequately controlled by available medications. They also face a 15 to 20 percent mortality rate due to SUDEP (Sudden Unexplained Death in Epilepsy), which are commonly seizure-related accidents such as drowning or infections. In most cases, Dravet Syndrome is caused by heterozygous de novo mutations or gene deletions of SCN1A, a gene encoding a brain voltage-gated sodium channel (Nav1.1).

The effectiveness of EPX-300 was discovered using a proprietary phenotype-based zebrafish drug screening platform. The zebrafish harbors 82 percent of human disease-associated genes, and shares many physiological and metabolic pathways with humans. Using the zebrafish model for Dravet Syndrome, drug candidates were identified from a screen of more than 3,000 drugs that suppress seizures and symptoms associated with neurological diseases.

"By receiving orphan drug designation for EPX-300, now all of our drug candidates including EPX-100 and EPX-200, have been granted orphan drug status for Dravet Syndrome from the FDA," says Dr. Hahn-Jun Lee, M.Sc., Ph.D., president and CEO of Epygenix Therapeutics, Inc. "As a result, we are now able to establish a diversified pipeline to support patients with Dravet Syndrome, and are now preparing a clinical testing of our drug candidates for patients as early as possible." 

Dr. Jules Mitchel, Ph.D., president at Target Health, Inc., in New York City, issued a statement: "Working together with Epygenix, the medical community, patients and their families, and the FDA, will allow for a rapid and efficient clinical development path to establish the efficacy and safety of EPX-300 for the treatment of Dravet Syndrome. Congratulations to Epygenix for taking this path where there is an unmet medical need."

Dr. Jack Parent, M.D., and William J Herdman, professor of neurology, co-director of the Comprehensive Epilepsy Center at the University of Michigan Medical School and one of the key scientific advisors of the company, said together that Epygenix has successfully made diversified pipelines to support Dravet Syndrome patients including non-responders to current treatment options. They further hope that EPX-300, together with EPX-100 and EPX-200, will be one of the important treatment options for Dravet Syndrome patients in a near future.

Under the U.S. Orphan Drug Act, the FDA's Office of Orphan Products Development provides sponsors with special status and incentives to facilitate the drug development for rare disease affecting fewer than 200,000 people in the U.S. Orphan Drug Designation provides seven years of market exclusivity if the drug candidate receives regulatory approval together with tax credits for qualified clinical trial cost, exemptions from certain FDA application fees, and assistance in clinical trial design.

To learn more about the company and their ongoing work, visit Epygenix.com.

About Epygenix Therapeutics, Inc.

Epygenix Therapeutics, Inc. is a precision medicine-based biopharmaceutical company focused on discovering and developing drugs to treat rare and intractable genetic epilepsy in childhood, such as Dravet Syndrome. Epygenix is currently focused on developing EPX-100, EPX-200 and EPX-300. These drug candidates abolish convulsive behavior and electrographic seizure activity and were discovered in a zebrafish Dravet Syndrome model which mimics the human pathology. For more information, please visit Epygenix.com.

About EPX-300

EPX-300 is an FDA-approved drug for the treatment of major depression disorder which acts via modulation of 5HT signaling pathways. EPX-300 suppressed spontaneous convulsive behavior and electrographic seizures in zebrafish Dravet Syndrome models.

Media Contact

Hahn-Jun Lee, M.Sc., Ph.D.
Phone: 201-724-1786
Email: hahnjun7@epygenix.com

View original content with multimedia:http://www.prnewswire.com/news-releases/epygenix-therapeutics-receives-us-fda-orphan-drug-designation-for-epx-300-for-the-treatment-of-patients-with-dravet-syndrome-300508283.html


'/>"/>
SOURCE Epygenix Therapeutics, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 17, 2019 , ... ... the MDA for their fourth annual national “Be Their Muscle” philanthropic event, and ... the lives of kids and adults with muscular dystrophy, ALS and related neuromuscular ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... Gwinnett ... an established and trusted provider of complete dental care, including general and preventative care ... is staffed with a large team of extensively trained dentists, Dr. Kell Gallaher, Dr. ...
(Date:7/17/2019)... (PRWEB) , ... July 17, 2019 , ... ... device compliance and commercialization, has just released a new e-book on ... life science product development; they are both a small part of the compliance ...
Breaking Medicine Technology:
(Date:7/17/2019)... Mich. (PRWEB) , ... July 17, 2019 , ... Women’s Excellence is pleased to announce ... this summer in September. The new offices resides on the corner of Turrill Road ... listened! We are thrilled about the opening of our new office in Lapeer and ...
(Date:7/13/2019)... (PRWEB) , ... July 12, 2019 , ... ... announced the launch of its proprietary patient management platform, Ospitek “View”. Ospitek has ... center executives to deliver a fully customizable, intelligent, solution made specifically for surgical ...
(Date:7/12/2019)... ... July 12, 2019 , ... Rebecca Baxt, M.D., F.A.A.D. and Saida ... Docs for 2019. Located in Paramus, BAXT CosMedical is a renowned facility that believes ... dermatological care for the past 45 years. , NJ Top Docs, Dr. Rebecca Baxt ...
(Date:7/10/2019)... CHARLOTTE, N.C. (PRWEB) , ... July 10, 2019 ... ... brand (NYSE American: YCBD), has just announced that Olympians Lolo Jones and Kerri ... massive platform for cbdMD to provide CBD education and brand awareness to athletes, ...
(Date:7/9/2019)... ... July 10, 2019 , ... Women's Excellence is excited to offer laser vaginal rejuvenation. Laser ... such as , painful sex , vaginal dryness ... , urinary urgency , vaginal pH imbalances , recurrent ...
Breaking Medicine News(10 mins):